Icatibant Glenmark (Icatibant)

Icatibant is a selective antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the action of bradykinin, a peptide that causes blood vessels to become leaky and swell. This inhibition stops the cascade that leads to the rapid swelling seen in HAE attacks.

The dose of Icatibant Glenmark is determined by the prescribing clinician based on the patient’s condition and regulatory labeling. It is administered as a subcutaneous injection, and the prescriber decides the exact amount and frequency required for each acute HAE episode.

Safety data for Icatibant during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Icatibant Glenmark, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative to icatibant is plasma‑derived or recombinant C1‑esterase inhibitor replacement therapy. While C1‑inhibitors restore the deficient protein, icatibant directly blocks bradykinin receptors, offering a rapid, subcutaneous option that does not require intravenous infusion. Choice depends on patient preference, attack severity, and clinical guidelines.

Icatibant Glenmark should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary temperature excursions occur, consult the product label before use.

The medication is supplied as a sterile solution for subcutaneous injection. It can be administered by a healthcare professional or, after appropriate training, by the patient or caregiver using the pre‑filled syringe provided with the product.

The most serious risks include anaphylaxis or severe hypersensitivity reactions, unexpected angioedema unrelated to HAE, and significant hypotension. Patients should be monitored after the first injection and instructed to seek immediate medical attention if they experience signs of a severe allergic reaction.

Icatibant Glenmark is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients currently taking ACE inhibitors or other drugs that increase bradykinin levels, as they may have a heightened risk of angioedema.